Document 0306
 DOCN  M9490306
 TI    Use of a clinical laboratory database to estimate Toxoplasma
       seroprevalence among human immunodeficiency virus-infected patients.
       Overcoming bias in secondary analysis of clinical records.
 DT    9411
 AU    Mathews WC; Fullerton SC; Department of Medicine, University of
       California, San Diego.
 SO    Arch Pathol Lab Med. 1994 Aug;118(8):807-10. Unique Identifier :
       AIDSLINE MED/94338255
 AB    Knowledge of Toxoplasma seroprevalence among human immunodeficiency
       virus-infected patients identifies candidates for potential prophylaxis
       and may influence management among patients who present with mass
       lesions of the central nervous system. Toxoplasma antibody
       seroprevalence among persons with human immunodeficiency virus infection
       varies widely. We utilized an administrative and laboratory database
       (including 1599 patients with human immunodeficiency virus infection who
       were receiving medical care at the University of California-San Diego
       Medical Center, between July 1, 1986, and March 31, 1990) to estimate
       Toxoplasma seroprevalence. Of the 1599 patients, 344 underwent serum
       assays for Toxoplasma antibodies. The tested group was similar to other
       members of the cohort in distributions of sex, race, citizenship, and
       age. The overall mean (+/- SE) Toxoplasma seroprevalence was 16% +/- 2%.
       Potential bias in this estimate because of testing indication,
       misclassification, or testing frequency was small.
 DE    Acquired Immunodeficiency Syndrome/*IMMUNOLOGY  Adolescence  Adult  Aged
       Animal  Antibodies, Protozoan/*ANALYSIS  Child  Child, Preschool
       *Clinical Laboratory Information Systems  Cohort Studies  Enzyme-Linked
       Immunosorbent Assay  Female  Fluorescent Antibody Technique  Human
       Infant  Infant, Newborn  Male  Middle Age  Support, U.S. Gov't, P.H.S.
       Toxoplasma/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).